The technical trend for Ajanta Pharma . has transitioned from mildly bearish to bearish, signalling a cautious outlook in the near term. Weekly and monthly analyses of the Moving Average Convergence Divergence (MACD) indicator reveal a divergence: the weekly MACD remains mildly bullish, while the monthly MACD shows a mildly bearish stance. This divergence suggests short-term momentum may differ from longer-term trends.
Relative Strength Index (RSI) readings for both weekly and monthly periods currently show no definitive signal, indicating a neutral momentum without clear overbought or oversold conditions. Meanwhile, Bollinger Bands on weekly and monthly charts align with a bearish outlook, reflecting increased volatility and potential downward pressure on prices.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- Complete fundamentals package
- Technical momentum confirmed
- Reasonable valuation entry
Daily moving averages for Ajanta Pharma . indicate a bearish pattern, reinforcing the current technical trend. The Know Sure Thing (KST) indicator presents a bearish signal on the weekly chart and a mildly bearish signal on the monthly chart, further supporting the cautious stance. Dow Theory analysis shows a mildly bullish weekly signal contrasted by a mildly bearish monthly signal, highlighting the mixed nature of momentum across timeframes.
On-balance volume (OBV) data also reflects this duality, with a mildly bullish weekly reading and a mildly bearish monthly reading, suggesting that volume trends are not decisively favouring either buyers or sellers over the longer term. The stock’s 52-week high is ₹3,115.00, while the 52-week low is ₹2,022.05, placing the current price closer to the lower end of its annual range.
Comparing Ajanta Pharma .'s returns with the Sensex reveals a contrasting performance. Over the past week, the stock recorded a return of -4.59%, while the Sensex gained 0.96%. Over the one-month period, both the stock and Sensex showed similar returns of approximately 0.85% and 0.86%, respectively. Year-to-date and one-year returns for Ajanta Pharma . stand at -16.52% and -14.46%, contrasting with Sensex returns of 8.36% and 9.48% over the same periods.
Longer-term returns present a different picture, with Ajanta Pharma . outperforming the Sensex over three, five, and ten-year horizons. The stock’s three-year return is 97.02%, compared to the Sensex’s 37.31%. Over five years, Ajanta Pharma . shows a return of 140.42%, exceeding the Sensex’s 91.65%. The ten-year return for the stock is 177.36%, while the Sensex recorded 232.28% during this period, indicating strong historical growth despite recent technical adjustments.
Holding Ajanta Pharma . from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- Peer comparison ready
- Superior options identified
- Cross market-cap analysis
Ajanta Pharma .'s market capitalisation grade remains at 2, reflecting its standing within the Pharmaceuticals & Biotechnology sector. The recent adjustment in its mojo score to 38.0 and a change in mojo grade from Hold to Sell as of 15 Sep 2025 indicate a revision in evaluation based on technical parameters. The trigger for this change was recorded on 19 Nov 2025 under the technical_dot category, underscoring the influence of technical momentum shifts on the stock’s assessment.
Investors analysing Ajanta Pharma . should consider the mixed technical signals and the divergence between short-term and long-term indicators. While some weekly indicators suggest mild bullishness, the broader monthly and daily trends lean towards caution. The stock’s recent price movement below its previous close and proximity to its 52-week low highlight the importance of monitoring momentum and volume trends closely.
In summary, Ajanta Pharma . presents a complex technical picture with a blend of bearish and mildly bullish signals across various indicators. The stock’s performance relative to the Sensex over different timeframes further emphasises the need for a nuanced approach when evaluating its potential. Market participants should weigh these technical factors alongside fundamental considerations to make informed decisions.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
